Ann: Viraleze shows antiviral efficacy in COVID-19 patients, page-61

The statistical significance for the cohort under 45 IMO was met before end of trial for most in that cohort. Therefore there was no statistical significance to report on the date at the endpoint of the trial as most had already cleared the virus being younger healthier and therefore had no symptoms or effects to report on that date. For this read some likely didn’t complete and or comply with the questionnaire entirely because of this. This was indicated in the announcement. A flawed study trial design and small sample size for that cohort created a false negative across the entire study. More participants would have given more power to the trial and negated this perception of a trial failure. I don’t know if some on here just don’t understand this, don’t want to, or do understand but continue to deliberately create negative sentiment for personal motive. Beware. DYOR. Read the comments from those that ran the trial. They were very impressed with the performance of Viraleze.